Hyperinflammation and Hyperferritinemia in Critically Ill Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCharles University, Czech Republic
About this trial
Analysing trajectory of critically ill patients with signs of hyperinflammation
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
critically ill patients
admission between 01.01.2020 and 31.12.2024 (5yrs)
Disqualifiers
none
Trial population
critically ill patients; mix-cases medical ICU population
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
1,962 Participants
are grouped into 1 trial groupGroup A: critically ill patients
Trial outcomes
Primary outcomes
1
hyperferritinemia
trajectory of critically ill patients with significant hyperferritinemia and with regard to its dynamics; ferritin value cutt-off
Time frame
2025Secondary outcomes
1
etiology and association of hyperferritinemia
etiology and association of hyperferritinemia with infectioius a non-infectious diseases/conditions
Time frame
20252
mortality a morbidity
mortality a morbidity of patients with significant hyperferritinemia
Time frame
20253
treatment strategy
association of hyperferritinemia and treatment strategy
Time frame
20254
stratification
patient stratification according to hyperferritinemia/hyperinflammation
Time frame
2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: